What is Wild Type?
Founded in 2016, Wild Type is a San Francisco-based biotechnology company dedicated to the development of cultivated seafood. The firm utilizes proprietary cellular agriculture techniques to grow authentic fish tissue, effectively bypassing the need for conventional fishing or industrial fish farming. By focusing on the molecular structure of seafood, Wild Type aims to replicate the taste, texture, and nutritional profile of wild-caught species while significantly reducing the carbon footprint and ecological impact of the seafood supply chain. The company operates at the intersection of food science and sustainability, targeting a market segment that is increasingly prioritizing transparency and environmental stewardship in their dietary choices.
How much funding has Wild Type raised?
Wild Type has raised a total of $100M across 1 funding round:
Series B
$100M
Series B (2022): $100M with participation from S2G Ventures, Bezos Expeditions, Cargill, Temasek, L Catterton, Spark Capital, Charles River Ventures, and FootPrint Coalition
Key Investors in Wild Type
S2G Ventures
S2G Ventures is a multi-stage food and agriculture venture fund that invests in entrepreneurs meeting the shifting demands for healthy and sustainable food systems.
Bezos Expeditions
Bezos Expeditions is an investment firm founded by Jeff Bezos that focuses on a diverse range of sectors including technology, healthcare, and space exploration.
Cargill
Cargill Meat Solutions Corporation is a leading global processor and distributor of fresh meat products, committed to providing sustainable food solutions worldwide.
What's next for Wild Type?
With the successful closure of this major strategic investment, Wild Type is well-positioned to accelerate its research and development efforts and scale its production capabilities. The company is expected to focus on optimizing its manufacturing processes to achieve cost parity with conventional seafood, a critical milestone for mass-market adoption. Furthermore, the strategic backing from diverse investors suggests a roadmap that includes navigating regulatory frameworks and expanding distribution channels. As the firm transitions from development to commercialization, its ability to maintain product quality while scaling will be the primary determinant of its long-term market leadership in the burgeoning alternative protein industry.
See full Wild Type company page
